Revelation Biosciences receives Nasdaq deficiency notices for bid price and stockholders' equity; intends to appeal

REVELATION BIOSCIENCES, INC.

Nasdaq notified REVB of non-compliance with $1.00 minimum bid price rule as of October 16, 2024.
Company not eligible for 180-day cure period due to reverse stock splits exceeding 250:1 cumulative ratio over two years.
Also cited for stockholders' equity deficiency (rule 5550(b)(1)), but company believes it satisfied requirement as of Sept 30, 2024 via Q3 financing.
Company will request a hearing before Nasdaq hearings panel to stay any suspension or delisting pending appeal.
Trading of common stock (REVB) and warrants (REVBW) continues on Nasdaq Capital Market for now.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.